{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:57:56Z","timestamp":1775156276354,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Eosinophils may contribute to ulcerative colitis (UC) pathogenesis through inflammation and epithelial injury. Mirikizumab, a selective IL-23 inhibitor, has shown efficacy in moderate-to-severe UC. However, the relationship between eosinophils and treatment outcomes with IL-23 inhibition remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This post-hoc analysis of the LUCENT-1 trial evaluated trends in serum and histologic eosinophils as biomarkers for early response to mirikizumab induction therapy in UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Data from LUCENT-1 (NCT03518086) were analyzed to assess serum eosinophil counts and histologic eosinophil presence at baseline and week 12. Clinical response, remission, and endoscopic improvement were defined by modified Mayo score criteria. Logistic regression models, adjusted for factors including steroid use, prior biologic failure, disease severity, and albumin levels, assessed associations between baseline eosinophil levels and treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 928 participants, 66.6% achieved clinical response. Responders had higher baseline serum eosinophils (0.23\u2009\u00d7\u2009109\/L vs 0.19\u2009\u00d7\u2009109\/L, P\u2009\u2009=\u2009.001) and showed greater reductions at week 12. Elevated baseline eosinophils (\u22650.57\u2009\u00d7\u2009109\/L) were associated with higher rates of clinical response (80% vs 65.7%, aOR: 2.31, P\u2009=\u2009.013), remission (33.3% vs 25.1%, aOR: 1.91, P\u2009=\u2009.044), and endoscopic improvement (46.7% vs 33.8%, aOR: 2.33, P\u2009\u2009=\u2009.003). Reductions in histologic eosinophils were also linked to improved outcomes, especially in those with moderate\/marked baseline presence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Baseline eosinophil levels may predict response to mirikizumab and guide early treatment decisions. These findings support a potential role for eosinophils as biomarkers in UC management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf267","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:12:39Z","timestamp":1760530359000},"page":"634-642","source":"Crossref","is-referenced-by-count":0,"title":["Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9472-201X","authenticated-orcid":false,"given":"Emily C L","family":"Wong","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, McMaster University , Hamilton, ON, L8S 4K1,","place":["Canada"]},{"name":"Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON, L8S 4K1,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-2321","authenticated-orcid":false,"given":"Parambir S","family":"Dulai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Northwestern University , Chicago, IL, 60611,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K","family":"Marshall","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, McMaster University , Hamilton, ON, L8S 4K1,","place":["Canada"]},{"name":"Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON, L8S 4K1,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University , London, ON, N6A 3K7,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna , 1090, Vienna,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8436","authenticated-orcid":false,"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, McMaster University , Hamilton, ON, L8S 4K1,","place":["Canada"]},{"name":"Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON, L8S 4K1,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2026040214063382100_izaf267-B1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fimmu.2017.00484","article-title":"Eosinophils in autoimmune diseases","volume":"8","author":"Diny","year":"2017","journal-title":"Front Immunol"},{"key":"2026040214063382100_izaf267-B2","first-page":"255","article-title":"Histopathology of Crohn\u2019s disease and ulcerative colitis","volume":"18","author":"Geboes","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063382100_izaf267-B3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/gastro\/gou031","article-title":"Histological evaluation in ulcerative colitis","volume":"2","author":"DeRoche","year":"2014","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2026040214063382100_izaf267-B4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm0496-449","article-title":"Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia","volume":"2","author":"Garcia-Zepeda","year":"1996","journal-title":"Nat Med"},{"key":"2026040214063382100_izaf267-B5","doi-asserted-by":"crossref","first-page":"jjaf006","DOI":"10.1093\/ecco-jcc\/jjaf006","article-title":"Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease","volume":"19","author":"Wong","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026040214063382100_izaf267-B6","author":"ClinicalTrials.gov","year":"2022"},{"key":"2026040214063382100_izaf267-B7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"2026040214063382100_izaf267-B8","doi-asserted-by":"crossref","first-page":"e000373","DOI":"10.1136\/bmjgast-2020-000373","article-title":"Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation","volume":"7","author":"Alhmoud","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"2026040214063382100_izaf267-B9","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026040214063382100_izaf267-B10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"2026040214063382100_izaf267-B11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026040214063382100_izaf267-B12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ni.2031","article-title":"The encephalitogenicity of TH17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF","volume":"12","author":"El-Behi","year":"2011","journal-title":"Nat Immunol"},{"key":"2026040214063382100_izaf267-B13","doi-asserted-by":"crossref","first-page":"e90298","DOI":"10.1371\/journal.pone.0090298","article-title":"Tumour necrosis factor-\u03b1 regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-\u03baB and AP-1","volume":"9","author":"Kankaanranta","year":"2014","journal-title":"PLoS One"},{"key":"2026040214063382100_izaf267-B14","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.4049\/jimmunol.1000446","article-title":"Human eosinophils exert TNF-\u03b1 and granzyme A-mediated tumoricidal activity toward colon carcinoma cells","volume":"185","author":"Legrand","year":"2010","journal-title":"J Immunol"},{"key":"2026040214063382100_izaf267-B15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ecco-jcc\/jjac024","article-title":"The clinical significance of eosinophils in ulcerative colitis: a systematic review","volume":"16","author":"Mookhoek","year":"2022","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/634\/65489407\/izaf267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/634\/65489407\/izaf267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:06:42Z","timestamp":1775153202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/4\/634\/8341047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,24]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf267","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,11,24]]}}}